Renalytix AI Launches Trial To Identify COVID-19 Patients With Kidney Injury

The Mount Sinai spin-off believes its KindeyIntelX system can identify COVID-19 patients at high risk for long-term kidney damage.

MT2008_Kidney Illustration_692941285_1200.jpg
• Source: shutterstock.com

Renalytix AI plc  is working with several major US academic health centers to identify kidney-related complications and long-term outcomes in patients who have survived COVID-19.

“[COVID-19] has the potential to be another cause of chronic kidney disease that needs to be addressed,” Thomas McLain, Renalytix AI’s chief

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from In Vitro Diagnostics

More from Diagnostics